Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Vizimpro
|
| gptkbp:chemicalFormula |
C24H26ClN5O2S
|
| gptkbp:clinicalTrials |
gptkb:ARCHER_1009
Phase III ARCHER 1050 |
| gptkbp:contraindication |
hypersensitivity to dacomitinib
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
CYP3A4 inhibitors
CYP3A4 inducers high oral bioavailability inhibits_EGFR_phosphorylation |
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:healthcare |
do not crush or chew tablets
take on an empty stomach |
| https://www.w3.org/2000/01/rdf-schema#label |
Dacomitinib
|
| gptkbp:is_monitored_by |
electrolytes
liver function tests |
| gptkbp:isATypeOf |
1038916-66-1
|
| gptkbp:lastProduced |
2018
|
| gptkbp:mandates |
locally advanced or metastatic non-small cell lung cancer
|
| gptkbp:marketedAs |
Vizimpro
|
| gptkbp:numberOfStudents |
about 5-10 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
L01XE30
|
| gptkbp:patentType |
September 2018
|
| gptkbp:research |
ongoing studies for other cancers
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
interstitial lung disease
QT prolongation embryo-fetal toxicity severe skin reactions |
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash anorexia |
| gptkbp:startsAt |
45 mg once daily
|
| gptkbp:storage |
store at room temperature
protect from moisture |
| gptkbp:targets |
gptkb:EGFR
|
| gptkbp:triggerType |
EGFR_inhibitor
|
| gptkbp:usedFor |
non-small cell lung cancer
|
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
471.01 g/mol
|